{"id":2654,"date":"2018-03-26T06:31:02","date_gmt":"2018-03-26T06:31:02","guid":{"rendered":"https:\/\/touchneurology.com\/2018\/03\/26\/treatment-advances-in-parkinsons-disease-psychosis-transforming-the-standard-of-care-for-hallucinations-and-delusions\/"},"modified":"2022-03-15T14:34:04","modified_gmt":"2022-03-15T14:34:04","slug":"treatment-advances-in-parkinsons-disease-psychosis-transforming-the-standard-of-care-for-hallucinations-and-delusions","status":"publish","type":"post","link":"https:\/\/touchneurology.com\/parkinsons-disease\/journal-articles\/treatment-advances-in-parkinsons-disease-psychosis-transforming-the-standard-of-care-for-hallucinations-and-delusions\/","title":{"rendered":"Treatment Advances in Parkinson\u2019s Disease Psychosis\u2014Transforming the Standard of Care for Hallucinations and Delusions"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"YouTube video player\" src=\"https:\/\/www.youtube.com\/embed\/OEbXsU0AUtg\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><span data-mce-type=\"bookmark\" style=\"width: 0px;overflow: hidden;line-height: 0\" class=\"mce_SELRES_start\">\ufeff<\/span><\/iframe><\/p>\n<p class=\"_-Body-Text\"><a id=\"_idTextAnchor000\"><\/a>Pathologically, Parkinson\u2019s disease (PD) is characterized by the loss of dopaminergic neurons in the <span class=\"Italics\">substantia nigra<\/span> and the presence of Lewy bodies.<span class=\"Superior\">1<\/span> In a staging model proposed by Braak in 2003,<span class=\"Superior\">2<\/span> the presence of midbrain lesions are preceded by degeneration and Lewy bodies in lower brain stem nuclei. Indeed, non-motor features such as constipation, sleep disorders, hyposmia, and depression may precede motor symptoms by years and even decades (<span class=\"Italics\">Figure 1<\/span>).<span class=\"Superior\">3<\/span> Throughout the course of PD, it has become increasingly recognized that non-motor symptoms continue to occur as motor symptoms progress.<span class=\"Superior\">3<\/span><\/p>\n<p class=\"_-Body-Text\"><img loading=\"lazy\" decoding=\"async\" class=\" size-full wp-image-2649\" src=\"https:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2018\/03\/figure1-clinical-symptoms-and-time.png\" width=\"578\" height=\"506\" srcset=\"https:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2018\/03\/figure1-clinical-symptoms-and-time.png 578w, https:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2018\/03\/figure1-clinical-symptoms-and-time-300x263.png 300w\" sizes=\"(max-width: 578px) 100vw, 578px\" \/><\/p>\n<p class=\"_-Body-Text\">Of the one million people in the US who live with PD,<span class=\"Superior\">4<\/span> more than 50% will develop psychosis during the course of their disease.<span class=\"Superior\">5<\/span> Parkinson\u2019s disease psychosis (PDP) is clinically distinct from other psychotic disorders such as schizophrenia, and is characterized by hallucinations<span class=\"Superior\">6\u20138<\/span> and delusions.<span class=\"Superior\">6\u20139<\/span> Visual hallucinations \u2013 including presence or passage hallucinations \u2013 or illusions are most common. It is common for patients to report seeing animals or children (see case study). Tactile hallucinations may accompany visual hallucinations; other types include auditory (e.g., music, indistinct voices), olfactory, somatic and gustatory hallucinations.<span class=\"Superior\">6\u20138<\/span> Delusions frequently include beliefs of marital infidelity and relatives stealing money.<span class=\"Superior\">7,9\u201311<\/span><\/p>\n<p>__________________________________________________________________<\/p>\n<table id=\"table001\" class=\"Basic-Table\">\n<colgroup>\n<col class=\"_idGenTableRowColumn-1\" \/> <\/colgroup>\n<tbody>\n<tr class=\"Basic-Table _idGenTableRowColumn-2\">\n<td class=\"Basic-Table CellOverride-1\">\n<p class=\"_-1-Body-text-heading-1\">Presentation and medical history<\/p>\n<ul>\n<li class=\"_-Body-BULLETS\">Maria is 74 years old and was diagnosed with PD 7 years ago.<\/li>\n<li class=\"_-Body-BULLETS\">She also has osteoporosis, although she has not received treatment for it.<\/li>\n<li class=\"_-Body-BULLETS\">Maria has been taking carbidopa\/levodopa for 5 years, and although in the past this managed her motor symptoms fairly well, over the past year her motor symptoms have worsened.<\/li>\n<li class=\"_-Body-BULLETS\">She recently fell and broke her wrist, and as a result Maria\u2019s carbidopa\/levodopa dosage was increased to deal with her worsening motor symptoms.<\/li>\n<li class=\"_-Body-BULLETS\">She was also prescribed medication for her pain.<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>__________________________________________________________________<\/p>\n<p class=\"_-Body-Text\">This article reports on an Industry Therapeutic Update (sponsored by ACADIA Pharmaceuticals Inc.) which was held at the 69th\u00a0Annual\u00a0American Academy of Neurology (AAN) Meeting (April 22\u201328,\u00a02017) in Boston, MA, USA. The objectives of this Industry Therapeutic Update were to explore the pathophysiology, symptomology, diagnosis and impact of PDP, the role of serotonin signaling within PDP, and to examine the current standard of care for treatment for the condition. In addition, the proposed mechanism of action, efficacy, safety, and administration of pimavanserin as a treatment for hallucinations and delusions associated with PDP will be summarized.<\/p>\n<p class=\"_-1-Body-text-heading-1\">Diagnostic issues<\/p>\n<p class=\"_-Body-Text\"><span class=\"CharOverride-14\"><i>\u201cPDP is far more common than many of our patients are aware; they need to know that this is part of the underlying disease<\/i>.\u201d<\/span> \u2013 Stuart Isaacson<\/p>\n<p class=\"_-Body-Text\">PDP can be diagnosed according to the 2007 National Institute of Neurological Disorders and Stroke (NINDS) and National Institute of Mental Health (NIMH) provisional diagnostic criteria.<span class=\"Superior\">6<\/span> Diagnosis of PDP requires the presence of at least one of the following symptoms: hallucinations, illusions (i.e., misperception of actual stimuli in contrast to hallucinations which occur in the absence of real stimuli), delusions, or false sense of presence.<span class=\"Superior\">6<\/span> Associated features that may or may not occur in PDP include insight, dementia, and the patient may or may not be receiving drugs for treatment of PD. Symptoms must occur in patients with previously diagnosed PD and must be recurrent or continuous for at least 1 month. Other causes should be excluded, including delirium, dementia with Lewy bodies, and psychiatric disorders such as schizophrenia, schizoaffective disorder, delusional disorder or mood disorders with psychotic features.<span class=\"Superior\">6<\/span><\/p>\n<p class=\"_-Body-Text\">A validated, patient self-report questionnaire (NMSQuest) was used in a study (n=242) designed to identify the non-motor symptoms \u2013 including delusions and hallucinations \u2013 that may not have been disclosed to physicians.<span class=\"Superior\">12<\/span> Of the patients who completed the surveys and experienced symptoms, 41.5% experienced hallucinations and 65.2% experienced delusions they did not declare to their physicians. Patients may under-report PDP symptoms for a variety of reasons, including the fact that it may be unclear to patients that the non-motor symptoms they are experiencing are related to PD, and during time-restricted consultations, patients may simply not have enough time or forget to mention non-motor symptoms.<span class=\"Superior\">12,13 <\/span><\/p>\n<p>__________________________________________________________________<\/p>\n<table id=\"table002\" class=\"Basic-Table\">\n<colgroup>\n<col class=\"_idGenTableRowColumn-1\" \/> <\/colgroup>\n<tbody>\n<tr class=\"Basic-Table _idGenTableRowColumn-3\">\n<td class=\"Basic-Table CellOverride-1\">\n<p class=\"_-1-Body-text-heading-1\">Symptoms of Parkinson\u2019s disease psychosis<\/p>\n<ul>\n<li class=\"_-Body-BULLETS\">The reason for her visit is that Rebecca \u2013 Maria\u2019s daughter \u2013 reported that her mother has been seeing a black cat in her bedroom at night, despite having no animals in the house.<\/li>\n<li class=\"_-Body-BULLETS\">When asked about the cat, Maria explains that she knows the cat is not really there, but she enjoys seeing it.<\/li>\n<li class=\"_-Body-BULLETS\">Rebecca is disturbed by her mother\u2019s behavior.<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>__________________________________________________________________<\/p>\n<p class=\"_-Body-Text\">PDP often begins with hallucinations with retained insight<span class=\"Superior\">13<\/span> and, while the patients remain cognizant of these PDP symptoms, they are often able to cope without behavioral disturbances.<span class=\"Superior\">14<\/span> However, as PDP progresses, insight is often lost and delusions may occur;<span class=\"Superior\">6,13,15<\/span> patients may find these symptoms threatening and may respond or act aggressively, creating behavioral disturbances.<span class=\"Superior\">16<\/span> The majority of patients experiencing mild hallucinations progress to more severe symptoms;<span class=\"Superior\">13<\/span> additionally, caregiver burden increases.<span class=\"Superior\">17,18<\/span> In a case study review of 143 patients with PD who were admitted to a hospital, symptoms of psychosis accounted for 24% of admissions.<span class=\"Superior\">19<\/span> Further, a 4-year prospective study carried out in Norway (n=178) identified that patients with PD experiencing hallucinations were two and a half times more likely to be admitted into a nursing home than patients with PD without hallucinations.<span class=\"Superior\">20<\/span> In addition, mortality at 3 years was approximately 40% for patients with PD and symptoms of psychosis, based on an age-adjusted model with a baseline age of 75 years (n=230).<span class=\"Superior\">21<\/span><\/p>\n<p>__________________________________________________________________<\/p>\n<table id=\"table003\" class=\"Basic-Table\">\n<colgroup>\n<col class=\"_idGenTableRowColumn-1\" \/> <\/colgroup>\n<tbody>\n<tr class=\"Basic-Table _idGenTableRowColumn-4\">\n<td class=\"Basic-Table CellOverride-1\">\n<p class=\"_-1-Body-text-heading-1\">Progression of Parkinson\u2019s disease psychosis<\/p>\n<ul>\n<li class=\"_-Body-BULLETS\">On the second visit, Maria appears to be losing insight: she is now seeing the black cat more frequently and is buying cat food for it.<\/li>\n<li class=\"_-Body-BULLETS\">She told her daughter Rebecca to keep better control of the cat because she has almost tripped over it several times. In response, her daughter tried to explain that the cat was not real.<\/li>\n<li class=\"_-Body-BULLETS\">Maria is also becoming delusional, saying the nightly news anchor is talking directly to her and that Rebecca is stealing money from her.<\/li>\n<li class=\"_-Body-BULLETS\">Maria has been experiencing hallucinations and delusions that are potentially serious for her and disturbing to her daughter.<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>__________________________________________________________________<\/p>\n<p class=\"_-Body-Text\">Both intrinsic and extrinsic factors contribute to PDP. Intrinsic factors include those associated with disease progression (older age, PD severity and duration),<span class=\"Superior\">22<\/span> abnormalities of neurodegeneration (neurochemical abnormalities and visual processing deficits),<span class=\"Superior\">22\u201324<\/span> comorbid medical conditions (e.g., urinary tract infections [UTIs]) and\/or psychiatric conditions.<span class=\"Superior\">6,22<\/span> Extrinsic factors encompass anti-Parkinson drugs (e.g., higher levodopa dose, dopamine agonists) and other medications (e.g., anticholinergics),<span class=\"Superior\">6,22<\/span> and environmental factors (time of day and dim lighting).<span class=\"Superior\">6,25,26<\/span><\/p>\n<p class=\"_-1-Body-text-heading-1\">Pathophysiology of Parkinson\u2019s disease psychosis<\/p>\n<p class=\"_-Body-Text\">Emerging evidence \u2013 albeit from very small studies \u2013 indicates that psychosis can result from overactivation of both dopaminergic and serotonergic signaling.<span class=\"Superior\">1,23,27\u201329<\/span> In an imaging study of five patients with PD and eight control subjects, the patients with PD showed reduced serotonin transporter binding, with the greatest reductions in the forebrain.<span class=\"Superior\">28<\/span> A pilot study was conducted using the selective serotonin 2A receptor (5-HT<span class=\"Subscript\">2A<\/span>) ligand [<span class=\"CharOverride-9\">18<\/span>F]-setoperone during positron emission tomography of seven patients with PD and visual hallucinations, and seven age-matched patients with PD but not visual hallucinations.<span class=\"Superior\">23<\/span> Patients with PD and hallucinations were found to have increased 5-HT<span class=\"Subscript\">2A<\/span> receptor binding in several regions of the brain, including the ventral visual pathway.<span class=\"Superior\">23<\/span> In addition, results from the Parkinson\u2019s Progression Markers Initiative showed that patients (n=21) with early onset formed hallucinations had reduced baseline higher visual function and cortical thinning in the parietal, occipital and frontal cortex, as well as reduced hippocampal volume, compared with the overall PD cohort.<span class=\"Superior\">30<\/span> A challenge for clinicians treating patients for PD is that dopaminergic therapies for motor symptoms typically worsen psychosis,<span class=\"Superior\">22<\/span> but the reduction of anti-Parkinson medication to treat PDP can worsen motor symptoms.<span class=\"Superior\">31,32<\/span><\/p>\n<p class=\"_-Body-Text\"><span class=\"CharOverride-14\"><i>\u201cThese studies provide an evidence base that, by modulating serotonin, we might be able to improve the psychotic symptoms of hallucinations and delusions in PD. It is important to consider this new way of thinking about the genesis of PDP because it opens the door to a way of treating PDP without worsening motor symptoms.\u201d<\/i><\/span>\u2013 Stuart Isaacson<\/p>\n<p class=\"_-1-Body-text-heading-1\">Treating Parkinson\u2019s disease psychosis<\/p>\n<p class=\"_-Body-Text\"><span class=\"CharOverride-14\"><i>\u201cIt\u2019s a real paradigm shift in that we finally have an FDA-approved medication to treat PDP that does not worsen motor symptoms\u2026<\/i><\/span>\u201d \u2013 Daniel Kremens<\/p>\n<p class=\"_-Body-Text\">Pimavanserin (NUPLAZID<span class=\"Superior\">\u00ae<\/span>; ACADIA Pharmaceuticals Inc., San Diego, CA, USA) \u2013 which is an atypical antipsychotic \u2013 does not worsen motor symptoms, and is the first and only Food and Drug Administration (FDA)-approved treatment for hallucinations and delusions associated with PDP.<span class=\"Superior\">33<\/span> As with all drugs in this class, pimavanserin has a boxed warning regarding mortality in elderly patients with dementia-related psychosis.<span class=\"Superior\">33<\/span><\/p>\n<p class=\"_-Body-Text\"><span class=\"Italics\">In vivo<\/span>, pimavanserin binds to 5-HT<span class=\"Subscript\">2A<\/span> receptors with a five-fold higher selectivity over 5-HT<span class=\"Subscript\">2C<\/span> receptors. It has no appreciable affinity to dopaminergic receptors (including D<span class=\"Subscript\">2<\/span>) or to muscarinic, histaminergic, or adrenergic receptors.<span class=\"Superior\">33<\/span> Pimavanserin\u2019s mechanism of action in the treatment of hallucinations and delusions associated with PDP is unknown although it may be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT<span class=\"Subscript\">2A<\/span> receptors, and to a lesser extent, at serotonin 5-HT<span class=\"Subscript\">2C<\/span> receptors.<span class=\"Superior\">33<\/span><\/p>\n<p>__________________________________________________________________<\/p>\n<table id=\"table004\" class=\"Basic-Table\">\n<colgroup>\n<col class=\"_idGenTableRowColumn-1\" \/> <\/colgroup>\n<tbody>\n<tr class=\"Basic-Table _idGenTableRowColumn-3\">\n<td class=\"Basic-Table CellOverride-1\">\n<p class=\"_-1-Body-text-heading-1\">Treatment of Parkinson\u2019s disease psychosis<\/p>\n<ul>\n<li class=\"_-Body-BULLETS\">Maria\u2019s neurologist prescribed her 34 mg of pimavanserin to treat the hallucinations and delusions she is experiencing.<\/li>\n<li class=\"_-Body-BULLETS\">Her neurologist reminded her and Rebecca that it is important to take pimavanserin each day and the hallucinations may begin to decrease from baseline as early as 2 weeks, though it may take up to 6 weeks to see the full benefits.<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>__________________________________________________________________<\/p>\n<p class=\"_-1-Body-text-heading-1\">Pimavanserin pivotal phase 3 clinical study<\/p>\n<p class=\"_-Body-Text\">A placebo-controlled, randomized, parallel-group study of 199 patients with PDP was conducted to determine whether pimavanserin can reduce hallucinations and delusions associated with PDP effectively.<span class=\"Superior\">34<\/span> Eligible participants entered a 2-week nonpharmacological lead-in phase, in which patients received brief psychological therapy adapted for PD. Subsequently, patients were randomly allocated (1:1) to receive pimavanserin 34 mg per day or matched placebo for 6 weeks. The primary outcome was antipsychotic benefit as assessed by central, independent raters with the Parkinson\u2019s disease-adapted scale for assessment of positive symptoms (SAPS-PD). The SAPS-PD is a nine-item scale, rated from 0 to 5, that includes hallucinations (five items) and delusions (four items) (<span class=\"Italics\">Figure 2<\/span>).<span class=\"Superior\">9<\/span> A 2.33-point change on the SAPS-PD is associated with a 1.00-point change on the Clinical Global Impression-Improvement scale (CGI-I)<span class=\"Superior\">9<\/span> indicating that a 3.00-point improvement on the SAPS-PD can mean the difference between daily and occasional symptoms of psychosis.<span class=\"Superior\">35<\/span> The secondary endpoint was change in the Unified Parkinson\u2019s Disease Rating Scale (UPDRS) Parts II + III.<span class=\"Superior\">33,34<\/span><\/p>\n<p class=\"_-Body-Text\">Key inclusion criteria were: age \u226540 years; PD diagnosis \u22651 year; psychotic symptoms occurred following PD onset, \u22651 month\u2019s duration, occurred at least weekly in the month before screening, and were frequent and severe enough to warrant treatment; stable on PD medication for at least 30 days prior to study start and throughout the 6-week study; neuropsychiatric inventory \u22656 or a score of \u22654 on either the Hallucinations or Delusions domain (at screening); and \u22653 on the SAPS-hallucination or -delusions global item and \u22653 on at least one other non-global item on the SAPS-PD (at baseline).<span class=\"Superior\">33,34<\/span> Patients with delirium or a mini-mental status exam (MMSE<span class=\"Superior\">36<\/span>) &lt;21 points were excluded.<span class=\"Superior\">33,34<\/span> Other exclusion criteria were psychosis secondary to toxic or metabolic disorder, psychosis following ablative stereotaxic surgery, presence of dementia concurrent or before PD, and uncontrolled serious medical illness.<span class=\"Superior\">33,34<\/span> In addition, antipsychotic drugs, centrally acting anticholinergics, or drugs that cause QT prolongation were prohibited.<span class=\"Superior\">33,34<\/span><\/p>\n<p class=\"_-Body-Text\"><img loading=\"lazy\" decoding=\"async\" class=\" size-full wp-image-2650\" src=\"https:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2018\/03\/figure2-the-scale-for-the-assessment.png\" width=\"565\" height=\"468\" srcset=\"https:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2018\/03\/figure2-the-scale-for-the-assessment.png 565w, https:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2018\/03\/figure2-the-scale-for-the-assessment-300x248.png 300w\" sizes=\"(max-width: 565px) 100vw, 565px\" \/><\/p>\n<p class=\"_-2-Body-Text-Heading-2\">Results<\/p>\n<p class=\"_-Body-Text\">Pimavanserin effectively diminished symptoms of hallucinations and delusions associated with PDP at 6 weeks (<span class=\"Italics\">Figure 3<\/span>).<span class=\"Superior\">33,34<\/span> The mean SAPS-PD baseline score for pimavanserin 34 mg was 15.9 and 14.7 for placebo.<span class=\"Superior\">33,34<\/span> For the primary endpoint, the point reduction on the SAPS-PD was -5.79 pimavanserin 34 mg and -2.73 placebo (p=0.0014).<span class=\"Superior\">33,34<\/span> Patients who received pimavanserin had a mean change that resulted in a 37% improvement from baseline compared with 14% for placebo.<span class=\"Superior\">34<\/span> The positive effect of pimavanserin on SAPS-PD improved as early as 2 weeks from baseline after starting treatment, with statistical significance seen at 4 and 6 weeks.<span class=\"Superior\">34<\/span> In an exploratory analysis, pimavanserin also reduced the individual hallucination and delusion domain scores of the SAPS-PD compared with placebo.<span class=\"Superior\">33<\/span> In total, 14 patients discontinued treatment after randomization but prior to the first visit post-baseline, resulting in a primary efficacy analysis population of 185. The mean age was 72.4 years for both pimavanserin 34 mg (n=95) and placebo (n=90).<span class=\"Superior\">34<\/span><\/p>\n<p class=\"_-Body-Text\">Approximately 65% of patients receiving pimavanserin experienced at least a 3-point reduction in hallucinations and delusions associated with PDP as measured by the total SAPS-PD score.<span class=\"Superior\">33<\/span> Illustrated in the case study of Maria (described previously), these improvements can be understood in terms of Maria being unsure whether or not she sees a black cat, and seeing a cat every day and buying food for it. Further, nearly 14% of patients taking pimavanserin experienced a complete response in hallucinations and delusions associated with PDP versus just 1% of patients taking placebo.<span class=\"Superior\">33<\/span> The change from baseline in UPDRS Parts II + III was similar between the pimavanserin 34\u00a0mg (n=92) and placebo groups (n=88; -1.4 and -1.7 respectively), indicating that there was no motor worsening associated with treatment.<span class=\"Superior\">33<\/span><\/p>\n<p class=\"_-Body-Text\"><img loading=\"lazy\" decoding=\"async\" class=\" size-full wp-image-2651\" src=\"https:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2018\/03\/figure3-primary-endpoint-of-pimavanserin.png\" width=\"564\" height=\"505\" srcset=\"https:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2018\/03\/figure3-primary-endpoint-of-pimavanserin.png 564w, https:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2018\/03\/figure3-primary-endpoint-of-pimavanserin-300x269.png 300w\" sizes=\"(max-width: 564px) 100vw, 564px\" \/><\/p>\n<p class=\"_-Body-Text\"><img loading=\"lazy\" decoding=\"async\" class=\" size-full wp-image-2652\" src=\"https:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2018\/03\/table1-adverse-reactions-reported.png\" width=\"565\" height=\"376\" srcset=\"https:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2018\/03\/table1-adverse-reactions-reported.png 565w, https:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2018\/03\/table1-adverse-reactions-reported-300x200.png 300w\" sizes=\"(max-width: 565px) 100vw, 565px\" \/><\/p>\n<p class=\"_-Body-Text\">Overall, pimavanserin was well tolerated in the 6-week placebo-controlled trials, with the most common adverse events being peripheral edema and confused state (see full adverse events in <span class=\"Italics\">Table 1<\/span>). A total of 8% (16\/202) of pimavanserin 34 mg-treated patients and 4% (10\/231) of placebo-treated patients discontinued because of adverse reactions. The adverse reactions that occurred in more than one patient and with an incidence at least twice that of placebo were: hallucinations (2% pimavanserin 34 mg versus &lt;1% placebo), UTIs (1% pimavanserin 34 mg versus &lt;1% placebo), and fatigue (1% pimavanserin 34 mg versus 0% placebo).<span class=\"Superior\">33<\/span><\/p>\n<p class=\"_-1-Body-text-heading-1\">Clinical program for pimavanserin<\/p>\n<p class=\"_-Body-Text\">\u201c<span class=\"CharOverride-14\"><i>This drug has what has been termed cumulative pharmacokinetics in that a steady state in C<sub>max<\/sub> is gradually achieved around 10\u201312 days. When you begin pimavanserin 34 mg\/day without titration, as per label, you can reach the steady state that has been associated in the clinical trial with clinical efficacy and tolerability\u2026 In a sense, it self-titrates by gradually increasing its concentration in the plasma before reaching steady state<\/i><\/span>.\u201d \u2013 Stuart Isaacson<\/p>\n<p class=\"_-Body-Text\"><img loading=\"lazy\" decoding=\"async\" class=\" size-full wp-image-2653\" src=\"https:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2018\/03\/figure4-simulation-of-a-typical.png\" width=\"566\" height=\"521\" srcset=\"https:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2018\/03\/figure4-simulation-of-a-typical.png 566w, https:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2018\/03\/figure4-simulation-of-a-typical-300x276.png 300w\" sizes=\"(max-width: 566px) 100vw, 566px\" \/><\/p>\n<p class=\"_-Body-Text\">Across the clinical trial program, more than 1,200 people have been exposed to at least one oral dose of pimavanserin; 616 were patients with hallucinations and delusions associated with PDP.<span class=\"Superior\">33<\/span> Additional clinical trial experience in patients with hallucinations and delusions associated with PDP is derived from two open-label, safety extension studies (n=497).<span class=\"Superior\">33<\/span> As of April 2016, more than 300 patients have been treated for &gt;6 months; &gt;270 have been treated for at least 12 months; and &gt;150 have been treated for at least 24 months.<span class=\"Superior\">33<\/span><\/p>\n<p class=\"_-Body-Text\">The clinical trial program included a pharmacokinetic study (<span class=\"Italics\">Figure 4<\/span>), which found that the half-life was 57 hours, whereas the time to reach maximum plasma concentration was 6 hours (range 4\u201324).<span class=\"CharOverride-9\">33<\/span> A high-fat meal had no significant effect on rate and extent of pimavanserin exposure.<span class=\"Superior\">33<\/span> Concomitant use with drugs known to prolong the QT interval, including Class 1A or Class 3 antiarrhythmics (i.e., quinidine, procainamide, disopyramide, amiodarone, sotalol), certain antipsychotics (i.e., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (i.e., gatifloxacin, moxifloxacin), should be avoided as they may add to the QT effects of pimavanserin and increase the risk of cardiac arrhythmia.<span class=\"Superior\">33<\/span> CYP3A4 is the major enzyme responsible for pimavanserin metabolism and pimavanserin can interact with strong CYP3A4 inhibitors and CYP3A4 inducers. Examples of strong CYP3A4 inhibitors are: itraconazole, ketoconazole, clarithromycin, and indinavir, and strong CYP3A4 inducers include: rifampin, carbamazepine, phenytoin, and St. John\u2019s wort.<span class=\"Superior\">33<\/span> The recommended dose of pimavanserin is 34 mg once daily (any time of day), without titration; pimavanserin can be taken with or without food.<span class=\"Superior\">33<\/span> However, the recommended dose of pimavanserin when co-administered with a strong CYP3A4 inhibitor is 17 mg, taken orally as one tablet once daily.<span class=\"Superior\">33<\/span> When pimavanserin is co-administered with a strong CYP3A4 inducer, patients should be monitored for reduced efficacy and the dosage increased if required.<span class=\"Superior\">33<\/span> Based on pharmacokinetic studies, no dosage adjustment of carbidopa\/levodopa is required when administered concomitantly with pimavanserin.<span class=\"Superior\">33<\/span><\/p>\n<p class=\"_-1-Body-text-heading-1\">Use in elderly populations<\/p>\n<p class=\"_-Body-Text\">In the 6-week, placebo-controlled studies for pimavanserin, patients up to 90 years were included;<span class=\"Superior\">35<\/span> 49% of the patients were 65\u201375 years old and 31% were &gt;75 years old.<span class=\"Superior\">33<\/span> Patients were required to be 40 years of age or more for inclusion, as well as have an MMSE score greater than 21 so that patients were able to self-report symptoms.<span class=\"Superior\">33<\/span> In the pooled population of patients enrolled in 6-week, placebo-controlled studies (n=614), 27% had MMSE scores of 21\u201324 compared with 73% with scores \u226525.<span class=\"Superior\">33<\/span> No clinically meaningful differences in safety or effectiveness were noted between the two groups.<span class=\"Superior\">33<\/span> Thus, no dose adjustment is necessary for elderly patients.<\/p>\n<p class=\"_-1-Body-text-heading-1\">Conclusions<\/p>\n<p class=\"_-Body-Text\">More than 50% of patients with PD develop PDP at some point during the course of PD, and the symptoms generally worsen with time.<span class=\"Superior\">5,13<\/span> Evidence suggests the symptoms of psychosis can be the result of excessive serotonergic activity in the raphe nuclei.<span class=\"Superior\">1,27,29<\/span> Pimavanserin is the only FDA-approved treatment for hallucinations and delusions associated with PDP.<span class=\"Superior\">33 <\/span>Treatment with pimavanserin reduces hallucinations and delusions in patients with PDP without impacting motor function.<span class=\"Superior\">33<\/span> The recommended dose of pimavanserin is 34 mg, once daily, without titration and without a dosage adjustment in concomitant carbidopa\/levodopa.<span class=\"Superior\">30<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\ufeff Pathologically, Parkinson\u2019s disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies.1 In a staging model proposed by Braak in 2003,2 the presence of midbrain lesions are preceded by degeneration and Lewy bodies in lower brain stem nuclei. Indeed, non-motor features such as constipation, [&hellip;]<\/p>\n","protected":false},"author":101775,"featured_media":2655,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","rank_math_lock_modified_date":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2654","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","vocabulary_1-parkinsons-disease","vocabulary_1-psychiatric-disorders"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/posts\/2654"}],"collection":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/users\/101775"}],"replies":[{"embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/comments?post=2654"}],"version-history":[{"count":7,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/posts\/2654\/revisions"}],"predecessor-version":[{"id":29595,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/posts\/2654\/revisions\/29595"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media\/2655"}],"wp:attachment":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media?parent=2654"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/categories?post=2654"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/tags?post=2654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}